Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Willemse SB, Baak LC, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JT, Depla AC, Tuynman H, van Nieuwkerk CM, Schinkel CJ, Kwa D, Reesink HW, van der Valk M. Willemse SB, et al. J Viral Hepat. 2016 Dec;23(12):950-954. doi: 10.1111/jvh.12567. Epub 2016 Jul 13. J Viral Hepat. 2016. PMID: 27405785
Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.
van Dijk M, Kracht PAM, Arends JE, Blokzijl H, Burger DM, van Erpecum KJ, van Hoek B, de Knegt RJ, Posthouwer D, Ramsoekh D, Rijnders BJA, Schinkel J, Willemse SB, van der Valk M, Drenth JPH, Behalf Of The HepNed Study Group O. van Dijk M, et al. Among authors: willemse sb. Neth J Med. 2019 May;77(4):131-138. Neth J Med. 2019. PMID: 31502544 Free article.
Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis.
Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, Raben D, D'Arminio Monforte A, Dabis F, Van Der Valk M; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord. Willemse S, et al. J Viral Hepat. 2019 Oct;26(10):1224-1228. doi: 10.1111/jvh.13146. Epub 2019 Jun 20. J Viral Hepat. 2019. PMID: 31136059 Free PMC article. No abstract available.
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: willemse sb. Antiviral Res. 2017 Oct;146:139-145. doi: 10.1016/j.antiviral.2017.08.016. Epub 2017 Aug 24. Antiviral Res. 2017. PMID: 28844749 Free PMC article.
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. van der Ree MH, et al. Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11. Lancet. 2017. PMID: 28087069 Clinical Trial.
Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.
Stelma F, van der Ree MH, Sinnige MJ, Brown A, Swadling L, de Vree JML, Willemse SB, van der Valk M, Grint P, Neben S, Klenerman P, Barnes E, Kootstra NA, Reesink HW. Stelma F, et al. Among authors: willemse sb. Hepatology. 2017 Jul;66(1):57-68. doi: 10.1002/hep.29148. Epub 2017 Jun 7. Hepatology. 2017. PMID: 28295463 Free PMC article. Clinical Trial.
23 results